Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

44.3K
Overview
44.3K
Development of Immunocompetence01:22

Development of Immunocompetence

1.2K
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
1.2K
Vaccine Production01:23

Vaccine Production

152
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
152

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genotypic challenges in implementing broadly neutralizing antibody-based long-acting HIV-1 therapies.

Communications medicine·2026
Same author

Induction of broadly neutralizing HIV antibodies by a two-step mechanism informs vaccine design.

Science (New York, N.Y.)·2026
Same author

Oropouche virus: transmission, epidemiology, genetic diversity, and public health implications.

EClinicalMedicine·2026
Same author

Contemporary HIV-1 envelope pseudovirus panels for detecting and assessing B cell lineages with broadly neutralizing antibody potential.

PLoS pathogens·2026
Same author

Identification and genomic characterization of BA.3.2: a highly divergent BA.3-related SARS-CoV-2 lineage from southern Africa.

Virus evolution·2026
Same author

Env-antibody coevolution identifies B cell priming as the principal bottleneck to HIV V2 apex broadly neutralizing antibody development.

Science immunology·2026
Same journal

Dupilumab Emerges as an Effective Antibody Therapy for Eosinophilic Esophagitis.

Annual review of medicine·2026
Same journal

CAR T Cell Toxicities and Emerging Treatment Strategies.

Annual review of medicine·2026
Same journal

Transthyretin Amyloid Cardiomyopathy: A Rapidly Evolving Landscape.

Annual review of medicine·2026
Same journal

Accessibility of Somatic Genetic Testing for Cancer Treatment Decisions.

Annual review of medicine·2026
Same journal

Diffuse Parenchymal Lung Disease: Updates in Pathophysiology and Management.

Annual review of medicine·2026
Same journal

Revascularization for Ischemic Cardiomyopathy: Disproving the 45-Year-Old Concept of Hibernating Myocardium.

Annual review of medicine·2026
See all related articles

Related Experiment Video

Updated: May 5, 2026

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses
14:23

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses

Published on: August 31, 2014

15.2K

HIV-1 vaccine development after STEP.

Dan H Barouch1, Bette Korber

  • 1Division of Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115, USA. dbarouch@bidmc.harvard.edu

Annual Review of Medicine
|January 12, 2010
PubMed
Summary
This summary is machine-generated.

Developing an effective HIV-1 vaccine remains challenging due to viral diversity and difficulties in eliciting strong immune responses. Current strategies focus on overcoming these hurdles for next-generation vaccine candidates.

More Related Videos

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

10.0K
Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
10:58

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

9.6K

Related Experiment Videos

Last Updated: May 5, 2026

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses
14:23

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses

Published on: August 31, 2014

15.2K
Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

10.0K
Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
10:58

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

9.6K

Area of Science:

  • Immunology
  • Vaccinology
  • Virology

Background:

  • Despite over 25 years of research, a safe and effective human immunodeficiency virus type 1 (HIV-1) vaccine is still unavailable.
  • Previous antibody-based and T cell-based vaccine prototypes have not demonstrated efficacy in clinical trials.
  • Significant scientific obstacles hinder the progress of HIV-1 vaccine development.

Purpose of the Study:

  • To review the current landscape of HIV-1 vaccine research.
  • To outline strategies aimed at overcoming key challenges in HIV-1 vaccine development.
  • To discuss the path forward for creating effective HIV-1 vaccines.

Main Methods:

  • Review of existing scientific literature on HIV-1 vaccine research.
  • Analysis of challenges including viral diversity and immune response generation.
  • Identification and discussion of novel strategies for next-generation vaccine candidates.

Main Results:

  • The immense global diversity of HIV-1 presents a major obstacle.
  • Generating broadly reactive neutralizing antibodies and cellular immune responses remains difficult.
  • Next-generation vaccine candidates are in development but face significant scientific hurdles.

Conclusions:

  • Overcoming HIV-1's genetic diversity is crucial for vaccine success.
  • Developing strategies to elicit robust and broadly reactive immune responses is essential.
  • Continued research and innovative approaches are necessary to achieve an effective HIV-1 vaccine.